Prometheus has successfully raised $12 billion in capital, which is expected to bolster its efforts in artificial engineering within the biotech field.
This funding comes amid a backdrop of other important industry news, including the acquisition of a cancer drug by nonprofit Blood Cancer United.
Additionally, major companies like Lilly and Nvidia have made investments in Abridge, highlighting a trend of increasing financial activity in biotechnology.